Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2000-06-13
2002-12-03
Huff, Sheela (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C530S388100, C530S388150, C435S004000, C435S006120, C435S007100, C435S007210, C435S007200, C435S069100, C514S002600
Reexamination Certificate
active
06489444
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to nucleic acid and amino acid sequences of a human lysyl hydroxylase-like protein and to the use of these sequences in the diagnosis, treatment, and prevention of cancer and connective tissue disorders.
BACKGROUND OF THE INVENTION
Collagens are a family of nineteen different fibrous structural proteins that are found in several types of tissues. Collagens are the most abundant proteins in mammals, and are essential for the formation of connective tissue such as skin, bone, tendon, cartilage, blood vessels and teeth. Members of the collagen family can be distinguished from one another by the degree of cross-linking between collagen fibers and by the amount of carbohydrate units (e.g., galactose or glucosylgalactose) attached to the collagen fibers. Hydroxylated lysine residues (hydroxylysine) are essential for stability of cross-linking and as attachment points for carbohydrate units.
The enzyme lysyl hydroxylase catalyzes the hydroxylation of lysine residues to form hydroxylysine. Lysyl hydroxylase targets the lysine residue of the sequence X-lys-gly. Two isoforms of lysyl hydroxylase have been characterized, termed PLOD (procollagen-lysine, 2-oxoglutarate 5-dioxygenase) and PLOD2. The two enzymes share 75% sequence homology, with even higher similarity in the C-terminal region (Valtavaara, M. et al. (1997) J. Biol. Chem. 272: 6831-4).
Diminished lysyl hydroxylase activity is involved in certain connective tissue disorders. In particular mutations, including a truncation and duplications within the coding region of the gene for PLOD, have been described in patients with type VI Ehlers-Danos syndrome (Hyland, J. et al. (1992) Nature Genet. 2: 228-31; Hautala, T. et al. (1993) Genomics 15: 399-404).
The discovery of a new human lysyl hydroxylase-like protein and the polynucleotides encoding it satisfies a need in the art by providing new compositions which are useful in the diagnosis, treatment, and prevention of cancer and connective tissue disorders.
SUMMARY OF THE INVENTION
The invention features a substantially purified polypeptide, human lysyl hydroxylase-like protein (HLHLP), comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.
The invention further provides a substantially purified variant of HLHLP having at least 90% amino acid identity to the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention also provides an isolated and purified polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.
Additionally, the invention provides a composition comprising a polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention further provides an isolated and purified polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, as well as an isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.
The invention also provides an isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or a fragment of SEQ ID NO:2, and an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide sequence comprising SEQ ID NO:2 or a fragment of SEQ ID NO:2. The invention also provides an isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence comprising SEQ ID NO:2 or a fragment of SEQ ID NO:2.
The invention further provides an expression vector containing at least a fragment of the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. In another aspect, the expression vector is contained within a host cell.
The invention also provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide sequence encoding HLHLP under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.
The invention also provides a pharmaceutical composition comprising a substantially purified HLHLP having the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.
The invention further includes a purified antibody which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, as well as a purified agonist and a purified antagonist of the polypeptide.
The invention also provides a method for treating or preventing a cancer, the method comprising administering to a subject in need of such a treatment an effective amount of an antagonist of HLHLP.
The invention also provides a method for treating or preventing a connective tissue disorder, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising substantially purified HLHLP.
The invention also provides a method for treating or preventing a connective tissue disorder, the method comprising administering to a subject in need of such treatment an effective amount of an agonist of HLHLP.
The invention also provides a method for detecting a polynucleotide encoding HLHLP in a biological sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence encoding the polypeptide comprising SEQ ID NO:1 or a fragment of SEQ ID NO:1 to at least one of the nucleic acids of the biological sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding HLHLP in the biological sample. In one aspect, the nucleic acids of the biological sample are amplified by the polymerase chain reaction prior to the hybridizing step.
REFERENCES:
Bowie et al., Science vol. 247, pp. 1306-1310, Mar. 1990.*
Burgess et al., The Journal of Cell Biology, vol. 111, pp. 2129-2138, Nov. 1990.*
Lazar et al., Molecular and Cellular Biology, vol. 8, No. 3, pp. 1247-1252, Mar. 1988.*
Bork, Genome Research, vol. 10, pp. 398-400, 2000.*
Valtavaara, M., et al., “Cloning and Characterization of a Novel Human Lysyl Hydroxylase Isoform Highly Expressed in Pancreas and Muscle,”The Journal of Biological Chemistry, 272(11):6831-6834 (1997).
Hyland, J., et al., “a homozygous stop codon in the lysyl hydroxylase gene in two siblings with Ehlers-Danlos syndrome type VI,”Nature Genetics, 2:228-231 (1992).
Hautala, T., et al., “A Large Duplication in the Gene for Lysyl Hydroxylase Accounts for the Type VI Variants of Ehlers-Danlos Syndrome in Two Siblings,”Genomics, 15:399-404 (1993).
Kivirikko, K. and Myllyla, R., “Posttranslational Enzymes in the Biosynthesis of Collagen: Intracellular Enzymes,”Methods in Enzymology, 82:245-305 (1982).
Valtavaara, M., et al., (GI 2138313), GenBank Sequence Database (Accession U84573), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland 20894 1997.
Valtavaara, M., et al., (GI 2138314), GenBank Sequence Database (Accession U84573), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland 20894 1997.
Hautala, T., et al., (GI 190073), GenBank Sequence Database (Accession L06419), National Center for Biotechno
Bandman Olga
Corley Neil C.
Lal Preeti
Shah Purvi
Huff Sheela
Hunt Jennifer
Incyte Genomics Inc.
Incyte Genomics, Inc.
LandOfFree
Human lysyl hydroxylase-like protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human lysyl hydroxylase-like protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human lysyl hydroxylase-like protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2989895